Orbimed Advisors LLC Cuts Stock Holdings in argenex SE $ARGX

Orbimed Advisors LLC reduced its stake in argenex SE (NASDAQ:ARGX) by 6.2% during the 1st quarter, Holdings Channel reports. The fund owned 136,900 shares of the company’s stock after selling 9,100 shares during the quarter. argenex makes up approximately 1.8% of Orbimed Advisors LLC’s investment portfolio, making the stock its 12th biggest position. Orbimed Advisors LLC’s holdings in argenex were worth $99,971,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ARGX. Sound Income Strategies LLC acquired a new position in argenex during the 4th quarter worth $28,000. Whipplewood Advisors LLC purchased a new stake in argenex during the 1st quarter worth about $28,000. Sunbelt Securities Inc. acquired a new stake in argenex in the 3rd quarter valued at about $36,000. WPG Advisers LLC raised its position in argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after purchasing an additional 13 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of argenex by 268.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 81 shares of the company’s stock valued at $68,000 after buying an additional 59 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $918.22 on Monday. argenex SE has a fifty-two week low of $587.37 and a fifty-two week high of $953.58. The firm has a market capitalization of $57.44 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 1.21 and a beta of 0.45. The stock’s 50-day simple moving average is $868.28 and its 200-day simple moving average is $815.22.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, sell-side analysts forecast that argenex SE will post 26.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ARGX. Morgan Stanley boosted their price objective on argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Royal Bank Of Canada raised their target price on shares of argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a report on Friday. Bank of America lifted their price target on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. HC Wainwright reiterated a “buy” rating and set a $940.00 price target on shares of argenex in a report on Thursday, June 25th. Finally, Wedbush reissued an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,050.50.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.